HOT NEWS

Industry News

Wednesday, 23 April 2014   
SMARTT e-Patch is a winner at the French 'Worldwide Innovation Challenge'
Rhenovia Pharma, a biotechnology company specialized in the application of biosimulation to the research and development of new medicinal products, today announces that its SMARTT e-Patch project has won an award at the 'World Innovation Challenge'; founded by the President of France to identify future champions in the French economy. The innovative patch caters to the need for controlled administration of medicinal products in treating chronic conditions such as Alzheimer's disease. Support from the French State's program of investment for the future will help to industrialize the production of the patch within five years. The world market in this field is estimated to exceed EUR 22 billion (USD 31.5 billion) by 2015 (source: MarketsandMarkets, April 2013).
 
Tuesday, 22 April 2014   
'Dustman' protein helps bin cancer cells
Cancer researchers have discovered a new 'dustman' role for a molecule that helps a drug kill cancer cells according to a study, published in the journal Proceedings of the National Academy of Sciences (PNAS). The new findings point to a possible test that could identify patients who would be most responsive to a new class of cancer drugs and also those who might develop resistance, as well as suggesting new approaches to discovering more effective drugs. The study, by Cancer Research UK-funded scientists at The Institute of Cancer Research, London, shows that a molecule - known as 'Cullin-5' (CUL5) - behaves like a combined cleaner and dustman: sweeping up the proteins that tell cancer cells to divide continuously and consigning them to the cellular 'dustbin' for disposal.
 
Tuesday, 15 April 2014   
Positive trial data suggests Exenatide has the potential to be a disease modifying agent in Parkinson's disease
The Cure Parkinson's Trust, a charity founded by four people with Parkinson's disease, which is dedicated to facilitating and funding work towards a cure, today announces the publication of trial results which suggest possible disease modifying advantages twelve months after cessation of exposure to Exenatide in patients with Parkinson's disease. Exenatide has previously been identified as having a positive impact on insulin resistance. In a Parkinson's study published in May 2013, significant and clinically meaningful differences were demonstrated between the scores for those receiving Exenatide and the controls for both motor and cognitive symptoms 12 months after the start of the trial. Both the original and the follow-up trials were conducted at the UCL Institute of Neurology and were funded by The Cure Parkinson's Trust.
 

Research & Development

SMARTT e-Patch is a winner at the French 'Worldwide Innovation Challenge'

Rhenovia Pharma, a biotechnology company specialized in the application of biosimulation to the research and development of new medicinal products,...

'Dustman' protein helps bin cancer cells

Cancer researchers have discovered a new 'dustman' role for a molecule that helps a drug kill cancer cells according to...

Positive trial data suggests Exenatide has the potential to be a disease modifying agent in Parkinson's disease

The Cure Parkinson's Trust, a charity founded by four people with Parkinson's disease, which is dedicated to facilitating and funding...

Unexpected results in cancer drug trial

Research from the University of Southampton has shown a drug, used in combination with chemotherapy to treat advanced colorectal cancer,...

More in: Research & Development

Conferences & Events

Delegates from more than 30 countries to share the benefits of eHealth at WoHIT 2014

2 - 4 April 2014, Nice, France. The World of Health IT Conference and Exhibition 2014 (WoHIT 2014), taking place in Nice, France, presents a comprehensive international programme with 18...

HIMSS Europe Online Matchmaking at WoHIT 2014

2 - 4 April 2014, Nice, France. The World of Health IT 2014 (WoHIT 2014) will combine the following global audiences: influential European C-Suites, Nordic countries looking to invest, non-European...

Doctors 2.0 & You to address the "explosion of digital health tools" with new subjects, speakers, partners

5 - 6 June 2014, Paris, France. Doctors 2.0 & You, partner of Stanford Medicine X and known for its 360° inclusive perspective on the patient, the physician, and digital...

eHealth Forum 2014

12 - 14 May 2014, Athens, Greece. Organised by the Greek Presidency of the Council of the European Union in cooperation with the European Commission, the eHealth Forum 2014 brings...

mHealth Summit Europe 2014 Call for Papers

6 - 8 May 2014, Berlin, Germany. mHealth Summit Europe brings together global leaders in government, the private sector, industry, academia, providers and not-for-profit organizations from across the mHealth ecosystem....

More in: Conferences & Events

EC Pharmaceuticals

Medicines for children: more research, more availability and more information compared with 5 years ago

News image

Recently, the Commission has publisheed a progress report on medicines for children covering the five years since the Paediatric Regulation came into force. This preliminary snapshot points to improvements in...

New symbol to identify medicines undergoing additional monitoring

News image

An inverted triangle will shortly appear on the inside leaflet of certain medicinal products on the EU market, following a legal act adopted by the European Commission today. The symbol...

Launch of EU Rapid Alert platform for human Tissues and Cells

News image

A secure alert platform launched by the European Commission will improve the safety of patients undergoing transplantation and medical procedures involving human tissues and cells, e.g. bone marrow, cornea, skin,...

Commission proposes faster access to medicines for patients

News image

Medicines should enter the market faster. With this intention the European Commission has proposed today to streamline and reduce the duration of national decisions on pricing and reimbursement of medicines....

Pricing and reimbursement of medicines: Commission consults on EU transparency rules

News image

The European Commission has launched a public consultation in view of modernising rules on the transparency of Member States’ decisions regarding the pricing and reimbursement of medicines. The consultation invites...

More in: European Commission

EMA News

Committee for orphan medicines - overview of 2013 and looking ahead

News image

A total of 11 out of 81 medicines recommended for marketing authorisation by the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) in 2013 were intended...

PRAC recommends suspending use of Protelos/Osseor

News image

The European Medicines Agency's Pharmacovigilance Risk Assessment Committee (PRAC) has recommended that Protelos/Osseor should no longer be used to treat osteoporosis. In April 2013 the Agency had recommended restricting the...

EMA and US FDA release first conclusions of parallel assessment of quality-by-design applications

News image

The European Medicines Agency (EMA) and the United States Food and Drug Administration (US FDA) have published a joint question-and-answer document that outlines the conclusions of their first parallel...

European Medicines Agency creates Healthcare Professionals' Working Party

News image

The European Medicines Agency has established a formal Healthcare Professionals’ Working Party (HCPWP) to further involve this group of stakeholders in its range of activities. The role of the HCPWP...

More in: EMA